亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

培美曲塞 医学 内科学 卡铂 肿瘤科 化疗 危险系数 耐受性 中性粒细胞减少症 白细胞减少症 顺铂 不利影响 置信区间
作者
Shun Lü,Jie Wang,Yan Yu,Xinmin Yu,Yanping Hu,Xinghao Ai,Wei Wang,Xingya Li,Wu Zhuang,Yunpeng Liu,Weidong Li,Jiuwei Cui,Dong Wang,Wangjun Liao,Jianying Zhou,Zhehai Wang,Yuping Sun,Xiusong Qiu,Jie Gao,Yuanyuan Bao,Liang Liang,Mengzhao Wang
出处
期刊:Journal of Thoracic Oncology [Elsevier]
卷期号:16 (9): 1512-1522 被引量:164
标识
DOI:10.1016/j.jtho.2021.05.005
摘要

IntroductionTislelizumab, an anti–programmed cell death protein-1 antibody, was specifically engineered to minimize FcɣR macrophage binding to abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus chemotherapy may improve clinical outcomes in patients with advanced nonsquamous NSCLC (nsq-NSCLC).MethodsIn this open-label phase 3 trial (RATIONALE 304; NCT03663205), patients with histologically confirmed stage IIIB or IV nsq-NSCLC were randomized (2:1) to receive either arm A: tislelizumab plus platinum (carboplatin or cisplatin) and pemetrexed every 3 weeks (Q3Ws) or arm B: platinum and pemetrexed alone Q3W during induction treatment, followed by intravenous maintenance pemetrexed Q3W. The primary end point was progression-free survival (PFS) assessed by an independent review committee; clinical response and safety and tolerability were secondary end points.ResultsOverall, 332 patients (n = 222 [A]; n = 110 [B]) received treatment. With a median study follow-up of 9.8 months, PFS was significantly longer with tislelizumab plus chemotherapy compared with chemotherapy alone (median PFS: 9.7 versus 7.6 mo; hazard ratio = 0.645 [95% confidence interval: 0.462–0.902], p = 0.0044). In addition, response rates were higher and response duration was longer with combination therapy versus chemotherapy alone. Hematologic adverse events (AEs) were common in both treatment arms; the most reported AEs were grades 1 to 2 in severity. The most common grade greater than or equal to 3 AEs were associated with chemotherapy and included neutropenia (44.6% [A]; 35.5% [B]) and leukopenia (21.6% [A]; 14.5% [B]).ConclusionsAddition of tislelizumab to chemotherapy resulted in significantly prolonged PFS, higher response rates, and longer response duration compared with chemotherapy alone, identifying a new potential option for first-line treatment of advanced nsq-NSCLC irrespective of disease stage.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
皮老师完成签到,获得积分10
5秒前
打打应助savagecas采纳,获得10
10秒前
19秒前
savagecas发布了新的文献求助10
25秒前
赘婿应助Xulun采纳,获得10
51秒前
揽星色应助绝尘采纳,获得20
2分钟前
2分钟前
栗子发布了新的文献求助10
2分钟前
大个应助栗子采纳,获得10
2分钟前
xuexinxin完成签到,获得积分10
3分钟前
绝尘完成签到,获得积分10
3分钟前
嘉心糖完成签到,获得积分10
4分钟前
4分钟前
小奋青完成签到 ,获得积分10
5分钟前
科研通AI2S应助欻欻采纳,获得10
6分钟前
John完成签到,获得积分10
7分钟前
行隐应助科研通管家采纳,获得10
7分钟前
科研通AI2S应助spark810采纳,获得10
8分钟前
Kabutack完成签到,获得积分10
8分钟前
谢小盟完成签到 ,获得积分10
9分钟前
fendy完成签到,获得积分0
9分钟前
33应助闪闪飞阳采纳,获得20
9分钟前
9分钟前
耍酷秋完成签到,获得积分10
10分钟前
SciGPT应助耍酷秋采纳,获得10
10分钟前
闪闪飞阳完成签到,获得积分10
10分钟前
11分钟前
实力不允许完成签到 ,获得积分10
11分钟前
史前巨怪完成签到,获得积分10
11分钟前
11分钟前
科研通AI2S应助科研通管家采纳,获得10
11分钟前
11分钟前
猪皮恶人发布了新的文献求助10
11分钟前
呆呆完成签到 ,获得积分10
11分钟前
12分钟前
春风完成签到 ,获得积分10
14分钟前
bernice完成签到,获得积分10
14分钟前
15分钟前
15分钟前
drz完成签到 ,获得积分10
15分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
Diamonds: Properties, Synthesis and Applications 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099758
求助须知:如何正确求助?哪些是违规求助? 2751215
关于积分的说明 7612024
捐赠科研通 2403006
什么是DOI,文献DOI怎么找? 1275089
科研通“疑难数据库(出版商)”最低求助积分说明 616238
版权声明 599033